| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer | Journal of Clinical Oncology | 2004 | 1,046 |
| 2 | Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2 | Science | 2002 | 835 |
| 3 | American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001--Testing for Early Lung Cancer Detection | Ca-A Cancer Journal for Clinicians | 2001 | 724 |
| 4 | Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System | Cancer Discovery | 2020 | 664 |
| 5 | Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway | Trends in Molecular Medicine | 2015 | 660 |
| 6 | Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials | Journal of Clinical Oncology | 2008 | 544 |
| 7 | Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. | Journal of Clinical Investigation | 1997 | 522 |
| 8 | Muc2 Protects against Lethal Infectious Colitis by Disassociating Pathogenic and Commensal Bacteria from the Colonic Mucosa | PLoS Pathogens | 2010 | 521 |
| 9 | Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients | Blood | 2020 | 510 |
| 10 | Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer | Journal of Biological Chemistry | 2006 | 500 |
| 11 | Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining? | Journal of Clinical Oncology | 2005 | 479 |
| 12 | A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast | Journal of the National Cancer Institute | 2013 | 459 |
| 13 | American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors | Ca-A Cancer Journal for Clinicians | 2007 | 444 |
| 14 | Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 | Blood | 2005 | 397 |
| 15 | Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis | Blood | 2014 | 396 |
| 16 | γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity | Journal of Experimental Medicine | 2003 | 395 |
| 17 | Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism | Science Translational Medicine | 2017 | 383 |
| 18 | Adenoid cystic carcinoma of the head and neck – An update | Oral Oncology | 2015 | 377 |
| 19 | Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension | Cellular Microbiology | 2006 | 358 |
| 20 | Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years | Hum Vaccin | 2009 | 342 |
| 21 | Randomized Controlled Trial of Yoga Among a Multiethnic Sample of Breast Cancer Patients: Effects on Quality of Life | Journal of Clinical Oncology | 2007 | 331 |
| 22 | Update 2020: Management of Non-Small Cell Lung Cancer | Lung | 2020 | 331 |
| 23 | Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque | Circulation | 2020 | 319 |
| 24 | Seroconversion rates following COVID-19 vaccination among patients with cancer | Cancer Cell | 2021 | 297 |
| 25 | MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation | Blood | 2009 | 295 |
| 26 | Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | Journal of Clinical Oncology | 2009 | 262 |
| 27 | Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) | Leukemia | 2010 | 259 |
| 28 | HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum | Oncologist | 2005 | 258 |
| 29 | Radiotherapy Protocol Deviations and Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials | Journal of the National Cancer Institute | 2013 | 256 |
| 30 | Progress in adjuvant chemotherapy for breast cancer: an overview | BMC Medicine | 2015 | 256 |
| 31 | Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis | Journal of Hematology and Oncology | 2020 | 256 |
| 32 | Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery | Head and Neck | 2012 | 249 |
| 33 | EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment | Annals of Oncology | 2015 | 248 |
| 34 | Deregulation of DUX4 and ERG in acute lymphoblastic leukemia | Nature Genetics | 2016 | 244 |
| 35 | Cytokines, Inflammation and Colon Cancer | Current Cancer Drug Targets | 2011 | 243 |
| 36 | Therapy for Osteosarcoma | Paediatric Drugs | 2008 | 242 |
| 37 | Skin toxicities associated with epidermal growth factor receptor inhibitors | Targeted Oncology | 2009 | 241 |
| 38 | Macrophage-derived IL-1β stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3 | Oncogene | 2009 | 236 |
| 39 | Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia | Cancer Cell | 2013 | 230 |
| 40 | Leptomeningeal metastases in non-small-cell lung cancer | Lancet Oncology, The | 2018 | 227 |
| 41 | Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells | British Journal of Cancer | 2004 | 218 |
| 42 | Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy | Journal of Clinical Oncology | 2007 | 217 |
| 43 | Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group | Journal of Clinical Oncology | 2012 | 206 |
| 44 | The association of race and COVID-19 mortality | EClinicalMedicine | 2020 | 206 |
| 45 | DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling | Nature Medicine | 2016 | 204 |
| 46 | Macrophage-derived extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury | Nature Communications | 2016 | 197 |
| 47 | The third group of the B7‐CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7‐H3 | Immunological Reviews | 2017 | 197 |
| 48 | Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials | Blood | 2005 | 196 |
| 49 | HDACs and HDAC inhibitors in colon cancer | Epigenetics | 2008 | 195 |
| 50 | GPR30 predicts poor survival for ovarian cancer | Gynecologic Oncology | 2009 | 191 |
